Novartis Licenses Drug From Abogen for Up to $7.8 Bln
Novartis has agreed to a deal worth up to $7.8 billion to license a messenger RNA drug candidate from Abogen Biosciences, also securing options for future therapies. This move highlights a trend of major pharmaceutical companies seeking new drug candidates from Chinese biotechnology firms to bolster their pipelines.